A. Narkus

发表

The placebo effect in allergen-specific immunotherapy trials

O. Pfaar, M. Worm, R. Klinger, 2013, Clinical and Translational Allergy.

Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial

C. Bachert, L. Klimek, O. Pfaar, 2015, Clinical and Translational Allergy.

Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up.

O. Cromwell, J. Schnitker, D. Dokic, 2005, Prilozi.

Prospective validation of the “rhino conjunctivitis allergy-control-SCORE©” (RC-ACS©)

K. Reich, Annett Lotzin, I. Zschocke, 2012, Clinical and Translational Allergy.

Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber

A. Salapatek, A. Narkus, D. Häfner, 2013, Allergy.

Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.

H. Fiebig, O. Cromwell, A. Nandy, 2006, Immunology and allergy clinics of North America.

Prospective validation of ‘Allergy‐Control‐SCORETM’: a novel symptom–medication score for clinical trials

P. Matricardi, P M Matricardi, D Häfner, 2011, Allergy.

Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses.

P. Kuna, U. Wahn, P. Matricardi, 2011, The Journal of allergy and clinical immunology.

Efficacy and safety of preseasonal‐specific immunotherapy with an aluminium‐adsorbed six‐grass pollen allergoid

A. Narkus, O. Cromwell, O. Cromwell, 2005, Allergy.

Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies

A. Narkus, D. Häfner, V. Gödicke, 2014, Clinical and Translational Allergy.